A 52 week, open label extension to the randomized, double-blind, multicenter, multifactorial, placebo-controlled, parallel group study to evaluate the efficacy and safety of valsartan and amlodipine combined and alone in hypertensive patients.
Phase of Trial: Phase III
Latest Information Update: 07 Nov 2011
At a glance
- Drugs Amlodipine; Valsartan
- Indications Hypertension
- Focus Therapeutic Use
- Sponsors Novartis
- 07 Nov 2011 Actual end date (Mar 2005) added as reported by ClinicalTrials.gov.
- 28 Dec 2006 New trial record.